These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34225103)

  • 1. Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status.
    Liu HH; Li S; Cao YX; Guo YL; Zhu CG; Wu NQ; Li JJ
    Atherosclerosis; 2021 Aug; 330():29-35. PubMed ID: 34225103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.
    Duran EK; Aday AW; Cook NR; Buring JE; Ridker PM; Pradhan AD
    J Am Coll Cardiol; 2020 May; 75(17):2122-2135. PubMed ID: 32354380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome.
    Liu HH; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Qian J; Dou KF; Li JJ
    J Transl Med; 2022 May; 20(1):243. PubMed ID: 35619146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.
    Cao YX; Zhang HW; Jin JL; Liu HH; Zhang Y; Xu RX; Gao Y; Guo YL; Zhu CG; Hua Q; Li YF; Santos RD; Wu NQ; Li JJ
    J Lipid Res; 2020 Sep; 61(9):1254-1262. PubMed ID: 32641433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease.
    Liu HH; Cao YX; Jin JL; Zhang HW; Hua Q; Li YF; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Hong LF; Li JJ
    Heart; 2020 Aug; 106(16):1228-1235. PubMed ID: 32381650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study).
    Bittencourt MS; Santos RD; Staniak H; Sharovsky R; Kondapally R; Vallejo-Vaz AJ; Ray KK; Bensenor I; Lotufo P
    Am J Cardiol; 2017 May; 119(9):1352-1358. PubMed ID: 28302272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
    Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein profile and prevalence of cardiovascular risk factors in urban Moroccan women.
    El ayachi M; Mziwira M; Vincent S; Defoort C; Portugal H; Lairon D; Belahsen R
    Eur J Clin Nutr; 2005 Dec; 59(12):1379-86. PubMed ID: 16118656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.
    Mygind ND; Harutyunyan MJ; Mathiasen AB; Ripa RS; Thune JJ; Gøtze JP; Johansen JS; Kastrup J;
    Inflamm Res; 2011 Mar; 60(3):281-7. PubMed ID: 20972697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
    Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
    Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study.
    Dai W; Zhang Z; Zhao S
    Lipids Health Dis; 2018 Dec; 17(1):273. PubMed ID: 30509306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
    Shishehbor MH; Aviles RJ; Brennan ML; Fu X; Goormastic M; Pearce GL; Gokce N; Keaney JF; Penn MS; Sprecher DL; Vita JA; Hazen SL
    JAMA; 2003 Apr; 289(13):1675-80. PubMed ID: 12672736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
    Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.